Mixed Dyslipidemia
📧 Sign up to get email alerts when something new happens for Mixed Dyslipidemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-05-22FDA Approved: FENOFIBRATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries, Inc.'s supplemental application for fenofibrate (generic) under ANDA 201748, authorizing the mar…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: The Food Effect on PK Characteristics and Safety Profiles of PA-111 [Phase 1]
Phase 1 clinical trial update evaluating the effect of food on the pharmacokinetics and safety of PA-111 in patients with Mixed Dyslipidemia…
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. [Phase 3]
Phase 3 trial evaluating inclisiran as monotherapy in Chinese adults with elevated LDL-C and low-to-moderate ASCVD risk shows efficacy and s…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A [Phase 1]
A Phase 1 trial comparing pharmacokinetics and safety of PA-111 and PA-111A in adults with mixed dyslipidemia, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector
This entry reports the completion of a non-interventional study evaluating monthly 300 mg alirocumab (PRALUENT) administered using the SYDNE…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-02-05Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of AD-218 [Phase 3]
A Phase 3 clinical trial evaluating AD-218 for mixed dyslipidemia is currently recruiting. Sponsor: Addpharma Inc.
-
FDA approval · 2024-11-13FDA Approved: FENOFIBRATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods Pharmaceuticals Limited's fenofibrate as an Original Application generic (ANDA 210248). This marks the approval of a g…
-
FDA approval · 2024-11-06FDA Approved: ROSUVASTATIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the original application for rosuvastatin by Macleods Pharmaceuticals Limited, establishing a generic rosuvastatin product. Thi…
-
FDA approval · 2024-10-15FDA Approved: ROSUVASTATIN CALCIUM — Supplemental Application (Glenmark Pharmaceutials Inc., USA)
FDA approved a supplemental application for rosuvastatin calcium from Glenmark Pharmaceuticals, confirming regulatory approval of this gener…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia [Phase 3]
A Phase 3 clinical trial is evaluating JS002 as monotherapy for primary hypercholesterolemia and mixed dyslipidemia. The study is currently …
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
A completed real-world study evaluating Inclisiran in Chinese adults with primary hypercholesterolemia or mixed dyslipidemia.
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for ezetimibe (ANDA 210859). This is a routine supplemental approval for a gen…
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE — Supplemental Application (Marlex Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ezetimibe submitted by Marlex Pharmaceuticals, Inc., granting an update to the approved gene…
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE AND SIMVASTATIN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic Ezetimibe and Simvastatin combination from Aurobindo Pharma Limited.
-
FDA approval · 2024-04-30FDA Approved: PITAVASTATIN CALCIUM — Original Application (NorthStar RxLLC)
FDA approved NorthStar RxLLC's original application for pitavastatin calcium, a generic statin, to treat hyperlipidemia by lowering choleste…
-
FDA approval · 2024-03-29FDA Approved: EZETIMIBE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for ezetimibe filed by Quallent Pharmaceuticals Health LLC. This confirms approval of a new or m…
-
FDA approval · 2024-03-22FDA Approved: NEXLIZET — Supplemental Application (Esperion Therapeutics, Inc.)
The FDA approved a supplemental application for Nexlizet (bempedoic acid and ezetimibe) by Esperion Therapeutics.
-
FDA approval · 2024-02-21FDA Approved: ZETIA — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Zetia (ezetimibe) from Organon LLC.
-
FDA approval · 2024-02-08FDA Approved: FENOFIBRIC ACID — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an original application for fenofibric acid (generic) manufactured by Macleods Pharmaceuticals Limited.
-
FDA approval · 2024-01-31FDA Approved: FENOFIBRATE — Original Application (Chartwell RX, LLC.)
FDA approved fenofibrate (generic) under Original Application ANDA211407 for Chartwell RX, LLC. This marks the approval of a first generic v…
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: Study of ARO-ANG3 in Adults With Mixed Dyslipidemia [Phase 2]
Phase 2 study of ARO-ANG3 in adults with mixed dyslipidemia has completed and results have been posted.
-
FDA approval · 2023-09-20FDA Approved: FENOFIBRIC ACID — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for fenofibric acid from Aurobindo Pharma Limited, updating the product’s labeling as part of the su…
-
FDA approval · 2023-08-09FDA Approved: ZOCOR — Supplemental Application (Organon LLC)
FDA approved a Supplemental Application for ZOCOR (simvastatin) submitted by Organon LLC.
-
FDA label_change · 2023-08-04FDA Approved: EZALLOR SPRINKLE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for EZALLOR SPRINKLE (rosuvastatin) from Sun Pharmaceutical Industries.
-
FDA approval · 2023-03-27FDA Approved: FENOFIBRATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' Fenofibrate supplemental application.